Patents by Inventor Marion J. G. Bussemakers

Marion J. G. Bussemakers has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PCA3, PCA3 Genes, and Methods of Use
    Publication number: 20170073776
    Abstract: The present invention relates, in general, to a prostate-specific antigen, PCA3. In particular, the present invention relates to nucleic acid molecules coding for the PCA3 protein; purified PCA3 proteins and polypeptides; recombinant nucleic acid molecules; cells containing the recombinant nucleic acid molecules; antibodies having binding affinity specifically to PCA3 proteins and polypeptides; hybridomas containing the antibodies; nucleic acid probes for the detection of nucleic acids encoding PCA3 proteins; a method of detecting nucleic acids encoding PCA3 proteins or polypeptides in a sample; kits containing nucleic acid probes or antibodies; bioassays using the nucleic acid sequence, protein or antibodies of this invention to diagnose, assess, or prognose a mammal afflicted with prostate cancer; therapeutic uses; and methods of preventing prostate cancer in an animal.
    Type: Application
    Filed: November 30, 2016
    Publication date: March 16, 2017
    Applicants: Stichting Katholieke Universiteit, more particularly The University Medical Centre Nijmege, The Johns Hopkins University
    Inventors: Marion J.G. Bussemakers, William B. Isaacs
  • PCA3 genes
    Patent number: 9540696
    Abstract: The present invention relates, in general, to a prostate-specific antigen, PCA3. In particular, the present invention relates to nucleic acid molecules coding for the PCA3 protein; purified PCA3 proteins and polypeptides; recombinant nucleic acid molecules; cells containing the recombinant nucleic acid molecules; antibodies having binding affinity specifically to PCA3 proteins and polypeptides; hybridomas containing the antibodies; nucleic acid probes for the detection of nucleic acids encoding PCA3 proteins; a method of detecting nucleic acids encoding PCA3 proteins or polypeptides in a sample; kits containing nucleic acid probes or antibodies; bioassays using the nucleic acid sequence, protein or antibodies of this invention to diagnose, assess, or prognose a mammal afflicted with prostate cancer; therapeutic uses; and methods of preventing prostate cancer in an animal.
    Type: Grant
    Filed: September 23, 2013
    Date of Patent: January 10, 2017
    Assignees: Stichting Katholieke Universiteit, The University Medical Centre Nijmegen, The Johns Hopkins University
    Inventors: Marion J. G. Bussemakers, William B. Isaacs
  • PCA3, PCA3 GENES, AND METHODS OF USE
    Publication number: 20140017774
    Abstract: The present invention relates, in general, to a prostate-specific antigen, PCA3. In particular, the present invention relates to nucleic acid molecules coding for the PCA3 protein; purified PCA3 proteins and polypeptides; recombinant nucleic acid molecules; cells containing the recombinant nucleic acid molecules; antibodies having binding affinity specifically to PCA3 proteins and polypeptides; hybridomas containing the antibodies; nucleic acid probes for the detection of nucleic acids encoding PCA3 proteins; a method of detecting nucleic acids encoding PCA3 proteins or polypeptides in a sample; kits containing nucleic acid probes or antibodies; bioassays using the nucleic acid sequence, protein or antibodies of this invention to diagnose, assess, or prognose a mammal afflicted with prostate cancer; therapeutic uses; and methods of preventing prostate cancer in an animal.
    Type: Application
    Filed: September 23, 2013
    Publication date: January 16, 2014
    Applicants: The Johns Hopkins University, Stichting Katholieke Universiteit, more particularly The Univ. Medical Centre Nijmegen
    Inventors: Marion J.G. Bussemakers, William B. Isaacs
  • PCA3, PCA3 genes, and methods of use
    Patent number: 8551699
    Abstract: The present invention relates, in general, to a prostate-specific antigen, PCA3. In particular, the present invention relates to nucleic acid molecules coding for the PCA3 protein; purified PCA3 proteins and polypeptides; recombinant nucleic acid molecules; cells containing the recombinant nucleic acid molecules; antibodies having binding affinity specifically to PCA3 proteins and polypeptides; hybridomas containing the antibodies; nucleic acid probes for the detection of nucleic acids encoding PCA3 proteins; a method of detecting nucleic acids encoding PCA3 proteins or polypeptides in a sample; kits containing nucleic acid probes or antibodies; bioassays using the nucleic acid sequence, protein or antibodies of this invention to diagnose, assess, or prognose a mammal afflicted with prostate cancer; therapeutic uses; and methods of preventing prostate cancer in an animal.
    Type: Grant
    Filed: October 30, 2009
    Date of Patent: October 8, 2013
    Assignees: Stichting Katholieke Universiteit, more particularly The University of Medical Centre Nijmegen, The Johns Hopkins University
    Inventors: Marion J. G. Bussemakers, William B. Isaacs
  • PCA3, PCA3 GENES, AND METHODS OF USE
    Publication number: 20100047809
    Abstract: The present invention relates, in general, to a prostate-specific antigen, PCA3. In particular, the present invention relates to nucleic acid molecules coding for the PCA3 protein; purified PCA3 proteins and polypeptides; recombinant nucleic acid molecules; cells containing the recombinant nucleic acid molecules; antibodies having binding affinity specifically to PCA3 proteins and polypeptides; hybridomas containing the antibodies; nucleic acid probes for the detection of nucleic acids encoding PCA3 proteins; a method of detecting nucleic acids encoding PCA3 proteins or polypeptides in a sample; kits containing nucleic acid probes or antibodies; bioassays using the nucleic acid sequence, protein or antibodies of this invention to diagnose, assess, or prognose a mammal afflicted with prostate cancer; therapeutic uses; and methods of preventing prostate cancer in an animal.
    Type: Application
    Filed: October 30, 2009
    Publication date: February 25, 2010
    Inventors: Marion J.G. BUSSEMAKERS, William B. Isaacs
  • PCA3, PCA3 genes, and methods of use
    Patent number: 7632643
    Abstract: The present invention relates, in general, to a prostate-specific antigen, PCA3. In particular, the present invention relates to nucleic acid molecules coding for the PCA3 protein; purified PCA3 proteins and polypeptides; recombinant nucleic acid molecules; cells containing the recombinant nucleic acid molecules; antibodies having binding affinity specifically to PCA3 proteins and polypeptides; hybridomas containing the antibodies; nucleic acid probes for the detection of nucleic acids encoding PCA3 proteins; a method of detecting nucleic acids encoding PCA3 proteins or polypeptides in a sample; kits containing nucleic acid probes or antibodies; bioassays using the nucleic acid sequence, protein or antibodies of this invention to diagnose, assess or prognose a mammal afflicted with prostate cancer; therapeutic uses; and methods of preventing prostate cancer in an animal.
    Type: Grant
    Filed: October 28, 2005
    Date of Patent: December 15, 2009
    Assignees: Stichting Katholieke Universiteit, More Particularly the University Medical Centre Nijmegen, The Johns Hopkins University
    Inventors: Marion J. G. Bussemakers, William B. Isaacs
  • PCA3, PCA3 genes, and methods of use
    Patent number: 7008765
    Abstract: The present invention relates, in general, to a prostate-specific antigen, PCA3. In particular, the present invention relates to nucleic acid molecules coding for the PCA3 protein; purified PCA3 proteins and polypeptides; recombinant nucleic acid molecules; cells containing the recombinant nucleic acid molecules; antibodies having binding affinity specifically to PCA3 proteins and polypeptides; hybridomas containing the antibodies; nucleic acid probes for the detection of nucleic acids encoding PCA3 proteins; a method of detecting nucleic acids encoding PCA3 proteins or polypeptides in a sample; kits containing nucleic acid probes or antibodies; bioassays using the nucleic acid sequence, protein or antibodies of this invention to diagnose, assess, or prognose a mammal afflicted with prostate cancer; therapeutic uses; and methods of preventing prostate cancer in an animal.
    Type: Grant
    Filed: April 9, 1998
    Date of Patent: March 7, 2006
    Assignees: The Johns Hopkins University, Stichting Katholieke Universiteit more particularly The University Medical Centre
    Inventors: Marion J. G. Bussemakers, William B. Isaacs